Presentations by Program

Search by Program

In vitro Antibacterial Activity of Sulbactam Durlobactam (ETX2514) against 121 Recent Acinetobacter baumannii Isolates from Patients in India

Alita Miller, ID Week 2019

In vitro Antibacterial Activity and in vivo Efficacy of Sulbactam-Durlobactam (ETX2514) against Pathogenic Burkholderia Species

Alita Miller, ID Week 2019

Discovery of a Novel Series of Penicillin-binding Protein 3 Inhibitors to Treat Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Thomas Durand-Reville

Resistance to Sulbactam Durlobactam in Clinical Isolates of Acinetobacter baumannii is Rare and Maps to PBP3

Samir Moussa

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β-lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii-calcoaceticusComplex (ABC)

John O'Donnell, ASM Microbe 2019

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

John O'Donnell, ASM Microbe 2019

The Novel β-lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime Against Drug-Resistant Enterobacteriaceae

Sarah McLeod, ASM Microbe 2019

Cefpodoxime-ETX1317 Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance Mutations V240G, D179Y and D179Y/T243M in KPC-3 b-Lactamase

Adam Shapiro, ASM Microbe 2019

Novel Therapies Targeting Drug-Resistant Gonorrhea

John Mueller, ASM Microbe 2019

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

Sarah McLeod, ASM Microbe 2019